LBIO Lion Biotechnologies, Inc.

7.05
0  -2%
Previous Close 7.20
Open 7.20
Price To book 2.69
Market Cap 439.29M
Shares 62,310,000
Volume 207,822
Short Ratio 17.50
Av. Daily Volume 236,048

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated March 2017.
LN-145
Head and neck cancer
Phase 2 continues to enrol as of March 2016. Initial data to be presented in 2017.
LN-144
Refractory metastatic melanoma
Phase 2 to be initiated April 2017.
LN-145
Cervical cancer

Latest News

  1. IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Lion Biotechnologies, Inc. and Reminds Investors with Losses to Contact the Firm
  2. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Lion Biotechnologies, Inc. to Contact the Firm
  3. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lion Biotechnologies, Inc. of Class Action Lawsuit and Upcoming Deadline - LBIO
  4. EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lion Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm
  5. LBIO INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Lion Biotechnologies, Inc. and a Lead Plaintiff Deadline of June 13, 2017
  6. IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Lion Biotechnologies, Inc. and Reminds Investors with Losses to Contact the Firm
  7. Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Lion Biotechnologies, Inc. Investors and Encourages Investors to Contact the Firm
  8. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lion Biotechnologies, Inc. (LBIO) & Lead Plaintiff Deadline – June 13, 2017
  9. Lion Biotechnologies Announces New Manufacturing Services Agreement with PharmaCell
  10. INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lion Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm
  11. INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Lion Biotechnologies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 13, 2017 - LBIO
  12. EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Lion Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm
  13. Investor Alert: Kaplan Fox Announces Investigation Of Lion Biotechnologies, Inc.
  14. SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lion Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm
  15. The Klein Law Firm Announces a Class Action Filed on Behalf of Lion Biotechnologies, Inc. Shareholders and a Lead Plaintiff Deadline of June 13, 2017
  16. Lion Biotechnologies to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results on Monday, May 1, 2017
  17. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Lion Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm
  18. Pawar Law Group Announces Filing of Securities Class Action Lawsuit Against Lion Biotechnologies, Inc. - LBIO
  19. IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lion Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm
  20. SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Lion Biotechnologies, Inc. (NASDAQ: LBIO) To Contact Brower Piven Before The Lead Plaintiff Deadline

SEC Filings

  1. 8-K - Current report 17775147
  2. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17771274
  3. DEF 14A - Other definitive proxy statements 17771269
  4. 8-K - Current report 17768825
  5. 8-K - Current report 17755666
  6. PRE 14A - Other preliminary proxy statements 17746463
  7. CT ORDER - Confidential treatment order 17745999
  8. 8-K - Current report 17730276
  9. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17676399
  10. 8-K - Current report 17671998